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Portal hypertension commonly arises in the setting of advanced cirrhosis and is the direct consequence of increased resistance within the portal vasculature. This process can be complicated by the development of ascites and gastroesophageal varices, among other complications. Less commonly, portal hypertension can arise in a noncirrhotic patient secondary to obstruction of the splenic vein \[[@B1]\]. This phenomenon, known as left-sided portal hypertension (LSPH), is a rare clinical syndrome, which may result in the formation of isolated gastric varices (IGV). After the splenic vein becomes occluded, blood drains through the short gastric veins at increased pressures, resulting in dilation of submucosal structures and the formation of IGV \[[@B1]\]. These varices have the potential to rupture and subsequently result in significant gastrointestinal (GI) hemorrhage.

Although it comprises less than 5% of all cases of portal hypertension, the incidence of LSPH has been increasing over the past several decades, likely secondary to an increased awareness of its existence \[[@B1], [@B2]\]. Consequently, IGV due to LSPH should be considered in the differential diagnosis of patients presenting with upper GI bleeding, despite having normal liver function. The splenic vein obstruction or thrombosis that results in LSPH is usually seen in association with pancreatic disorders, secondary to the close anatomic relationship between the splenic vasculature and the pancreas \[[@B1]\]. Nonpancreatic etiologies of LSPH have been reported in the literature, but are much less common \[[@B1], [@B2], [@B3]\]. Splenectomy is currently the gold standard of treatment for bleeding IGV; however, less invasive alternatives, such as transcatheter splenic artery embolization are currently being explored. We present a rare case of LSPH and IGV in a patient with large B-cell lymphoma, who was ultimately treated with splenic artery embolization.
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The patient is a 73-year-old male with a past medical history of hyperlipidemia, hypertension, and obstructive sleep apnea who originally presented to hospital with a 3-day history of coffee ground emesis and melena. He also reported associated symptoms of dizziness, weakness, palpitations, and fatigue. In the Emergency Department, he was initially found to be hypotensive and tachycardic, with a hemoglobin level of 3.4 g/dl and an international normalized ratio of 1.29. He was aggressively resuscitated and transfused multiple units of packed red blood cells with appropriate response. Emergent esophagogastroduodenoscopy (EGD) was performed showing isolated bleeding varices (IGV) in the gastric fundus and was subsequently treated with argon plasma coagulation. The patient was then started on intravenous protonix and octreotide drips and transferred to our tertiary care center for evaluation of suspected underlying cirrhosis and for possible transjugular intrahepatic portosystemic shunt procedure.

The patient denied any previous history of liver disease, injection drug use, or current alcohol use. However, he did admit to having one previous episode of hematemesis over 40 years ago, which required blood transfusion. Upon further questioning, he also reported significant weight loss, with his weight decreasing from 318 to 280 pounds over a 6-month period. He underwent repeat EGD at our hospital, which again demonstrated multiple clusters of medium-sized IGV (IGV1 by Sarin Classification) (fig [1](#F1){ref-type="fig"}). Further work-up revealed normal liver function tests, and HIV/hepatitis screening was negative. Abdominal ultrasound showed patent hepatic and portal vasculature with no ultrasonographic evidence of cirrhosis. MRI and CT imaging demonstrated a large heterogeneously enhancing mass in the pancreatic tail with direct invasion into the spleen. There was also evidence of splenic vein thrombosis and enlarged abdominal lymph nodes. No metastatic disease was visualized in the liver or thorax (fig [2](#F2){ref-type="fig"}; the arrow is pointing to the perisplenic mass). Because of his combined clinical history and abnormal findings on imaging, there was initial concern for pancreatic malignancy, and he subsequently underwent CT-guided biopsy of the perisplenic mass. Surgery consultation was obtained to address possible resection of the mass to control the variceal bleed. However, given the patient\'s high likelihood of significant morbidity with surgical intervention, urgent splenectomy was not recommended. Rather, the patient underwent IR-guided splenic artery embolization to prevent future bleeding from his known gastric varices. He was discharged in stable condition with outpatient follow-up.

Pathology of the perisplenic mass was consistent with stage IVA-E diffuse large B-cell lymphoma (fig [3](#F3){ref-type="fig"}; pathology slide with hematoxylin and eosin staining). Immunohistochemical staining was positive for CD20, CD45, CD10, BCL6, and BCL2, and negative for CK19, CD3, CD5, cyclin D1, TTF-1, and TdT. MIB1 staining showed a proliferation rate of follicular structures up to 30%. PET-CT revealed intense fluorodeoxyglucose uptake within the known abdominal mass, with no additional metastatic involvement. The patient was evaluated by the Hematology Department to initiate R-CHOP chemotherapy. He reported no further episodes of melena or hematemesis during his follow-up appointments.
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As stated previously, LSPH is an uncommon clinical condition, which may result in the formation of IGV. LSPH typically results from obstruction of the splenic vein, which can occur with thrombosis or mass effect from adjacent structures. Many cases of IGV are discovered incidentally; however, rupture of these varices can also present as GI bleeding in the form of melena or hematemesis. The incidence of upper GI bleeding in patients with LSPH ranges from 45 to 72% in reported studies \[[@B1], [@B2], [@B3]\]. Our particular patient presented with gastric variceal bleeding in the form of coffee ground emesis and melena.

Pancreatic disorders account for the majority of cases of LSPH, secondary to the location of the splenic vein posterior to the pancreas. Acute and chronic pancreatitis, followed by pancreatic malignancies (adenocarcinomas, islet cell carcinomas, and cystadenomas), are among the most commonly reported causes of LSPH and IGV. Other pancreatic etiologies, such as pseudocysts, abscesses, and pancreas divisum, have also been reported in the literature \[[@B1], [@B2], [@B3]\]. Nonpancreatic etiologies of LSPH are less common but include metastatic malignancies (small cell lung cancer, renal cancer, gastric cancer, and colonic adenocarcinoma), lymphoma, surgical manipulations, retroperitoneal fibrosis, hypercoagulability disorders, and splenic artery aneurysms \[[@B1]\]. A diagnosis of LSPH is based on clinical history, radiographic imaging, and findings on upper endoscopy. Although somewhat invasive, angiography can also show filling deficits in the splenic vasculature and be used to confirm splenic vein thrombosis \[[@B1]\]. Endoscopic ultrasound has been shown to be superior to abdominal ultrasound for assessing the patency of the portal vasculature and should be considered when other diagnostic methods have failed to confirm the cause of bleeding gastric varices \[[@B1], [@B4]\]. Contrast-enhanced CT venography and MR angiography with gadopentetate dimeglumine have also occasionally been used to aid in diagnosis \[[@B5], [@B6]\].

Mortality from gastric variceal bleeds has been reported to be as high as 52% at 1 year, due to the limited efficacy of endoscopic therapy and the high rate of recurrent bleeding \[[@B1], [@B7]\]. Various options have been used to treat the bleeding from gastric varices, including endoscopic injection sclerotherapy, band ligation, and balloon-occluded retrograde transvenous obliteration, as well as injection of cyanoacrylate glue \[[@B1]\]. There are, however, more definitive treatment options for symptomatic patients with LSPH outside of endoscopic therapy.

Splenectomy is currently the gold standard of treatment for IGV secondary to LSPH from either pancreatic or nonpancreatic processes. Surgical removal of the spleen decreases venous outflow through collateral circulations and decompresses IGV to prevent future bleeding \[[@B8]\]. To the best of our knowledge, there have only been two other published case reports of large B-cell lymphoma causing upper GI bleeding from IGV \[[@B9],[@B10]\]. These cases were treated with splenectomy or chemotherapy alone. However, surgical splenectomy poses certain operative risks, especially in patients with multiple preexisting comorbidities. These risks include infection with encapsulated organisms, intra- and postoperative hemorrhage, thrombocytosis, pancreatitis, and gastric fistula formation, with reported morbidities and mortalities ranging from 8 to 52% and from 0 to 9%, respectively \[[@B11], [@B12]\]. One previous case report suggested that surgery might have been avoided in at least one case if the diagnosis of lymphoma had been considered preoperatively \[[@B9]\]. This illustrates the importance of recognizing the etiology of LSPH and considering less invasive management strategies when possible.

Transcatheter splenic artery embolization represents one of the less invasive alternatives to splenectomy as a treatment option for IGV, and it has been used with various degrees of success \[[@B1], [@B13]\]. During this procedure, a catheter is passed through the splenic artery near the splenic hilum, and coils are deployed to occlude arterial blood supply to the spleen. This subsequently decreases venous return, lowers portal pressure within the variceal collateral vessels, and ultimately prevents future bleeding from IGV. Splenic artery embolization has been shown to be as effective as splenectomy in lowering portal pressure and avoids potential complications of postsplenectomy sepsis or unregulated thrombocytosis. Studies have reported that the overall complication rate of splenic artery embolization is around 33--52% \[[@B14], [@B15]\]. However, most of these complications are minor and include symptoms of fever, leukocytosis, abdominal pain, and hydrothorax. More severe complications are rare, including splenic abscesses and splenic infarction \[[@B14], [@B15]\]. Our patient was able to undergo successful treatment with splenic artery embolization, thus avoiding the potential risks of surgery, and had cessation of his variceal bleeding.

Proximal portal decompressive procedures, such as transjugular intrahepatic portosystemic shunt, which are standard therapies in appropriate patients with liver cirrhosis and high portal pressures, do not have a role in the treatment of patients with isolated LSPH who typically are not cirrhotic and have normal portal pressures \[[@B1]\]. Recognizing this distinction emphasizes the importance of careful clinical evaluation for the cause of upper GI bleeding. Accurate diagnosis can help determine the safest and most effective approach to individualized therapy, thereby improving clinical outcomes.
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We present a case of successful treatment of bleeding IGV using a less invasive and less morbid approach through splenic artery embolization. This case highlights the need for an increased awareness of the diverse etiologies of LSPH and IGV, and the importance of accurate diagnosis of the cause of bleeding in these patients. In many cases, a nonsurgical approach can offer equally effective treatment with less morbidity.
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![MRI showing a mass in the pancreatic tail (arrow) with direct invasion into the spleen and associated splenic vein thrombosis.](crg-0010-0518-g02){#F2}

![Pathology slide with hematoxylin and eosin stain, consistent with diffuse large B-cell lymphoma.](crg-0010-0518-g03){#F3}
